Therapeutic compositions comprising imidazole and imidazolium compounds

1. A pharmaceutical composition comprising:

in an amount that is less than 0.1% w/w, and greater than 0%; or

in an amount that is less than 0.1% w/w, and greater than 0% w/w;

wherein any amount in % w/w is based upon the total weight of Compound A, Compound B, and Compound C;

wherein each A is independently an acidic functional group.

2. The pharmaceutical composition of claim 1 , wherein each A is CO 2 H.

3. The pharmaceutical composition of claim 1 , wherein each A is SO 3 H.

4. The pharmaceutical composition of claim 1 , wherein

is present in an amount that is less than 0.1% w/w, and greater than 0% w/w.

5. The pharmaceutical composition of claim 1 , wherein

is present in an amount that is less than 0.1% w/w, and greater than 0% w/w.

6. The pharmaceutical composition of claim 2 , wherein

is present in an amount that is less than 0.1% w/w, and greater than 0% w/w.

7. The pharmaceutical composition of claim 2 , wherein

is present in an amount that is less than 0.1% w/w, and greater than 0% w/w.

8. The pharmaceutical composition of claim 3 , wherein

is present in an amount that is less than 0.1% w/w, and greater than 0% w/w.

9. The pharmaceutical composition of claim 3 , wherein

is present in an amount that is less than 0.1% w/w, and greater than 0% w/w.

10. A pharmaceutical composition comprising:

zoledronic acid; and

in an amount that is less than 0.1% w/w, and greater than 0% w/w; or

in an amount that is less than 0.1% w/w, and greater than 0% w/w;

wherein any amount in % w/w is based upon the total weight of zoledronic acid, Compound 1, and Compound 2.

11. A dosage form comprising the pharmaceutical composition of claim 10 .

12. The dosage form of claim 11 , wherein

is present in an amount that is less than 0.05% w/w, and greater than 0% w/w.

13. The dosage form of claim 12 , wherein

is present in an amount that is less than 0.05% w/w, and greater than 0% w/w.

14. The dosage form of claim 11 , wherein the dosage form is an oral dosage form.

15. The dosage form of claim 14 , wherein

is present in an amount that is less than about 0.02%, and greater than 0% w/w.

16. The dosage form of claim 14 , wherein

is present in an amount that is less than about 0.02%, and greater than 0% w/w.

17. The dosage form of claim 15 , wherein

is present in an amount that is less than about 0.1%, and greater than 0% w/w.

18. The dosage form of claim 14 , wherein the zoledronic acid is present in a salt form.

19. The dosage form of claim 14 , wherein the zoledronic acid is present in a sodium salt form.

20. The dosage form of claim 14 , wherein the zoledronic acid is present in a disodium salt form.

21. A method of treating a disease or condition related to bone, cancer, or pain, comprising administering a dosage form of claim 14 to a mammal in need thereof;

wherein the disease or condition related to bone, cancer, or pain is inflammatory pain, arthritis pain, complex regional pain syndrome, lumbosacral pain, musculoskeletal pain, neuropathic pain, chronic pain, cancer-related pain, acute pain, postoperative pain, musculoskeletal pain, low back pain, rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, erosive osteoarthritis, a sero-negative or non-rheumatoid arthropathy, non-articular rheumatism, a peri-articular disorder, axial spondyloarthritis, ankylosing spondylitis, Paget's disease of bone, fibrous dysplasia, SAPHO syndrome, transient osteoporosis of the hip, vertebral crush fracture, osteoporosis, neuropathic pain, diabetic peripheral neuropathy, post-herpetic neuralgia, trigeminal neuralgia, a monoradiculopathy, phantom limb pain, central pain, cancer-related pain, lumbar nerve root compression, spinal cord injury, post-stroke pain, central multiple sclerosis pain, HIV-associated neuropathy, radio-therapy associated neuropathy, chemo-therapy associated neuropathy, or a combination thereof.